Cost of arthropathic diseases therapy with biologicals disease modifying drugs (bDMARs): a 5-year cost analysis at national level

Abstract This study analysed the changes in the reimbursed cost, prices and utilization of biological medicines for a 5-year time horizon, encompassing three major arthropathic diagnoses, rheumatoid arthritis (RA), psoriatic arthropathies (PsA) and ankylosing spondylitis (AS), from the point of view of the third-party payer in Bulgaria. National; population based; macroeconomic; top-down budget analysis was performed based on official data about the number of inhabitants, reimbursed diagnoses and medicines, reimbursed cost, treated patients, and prices of medicines. The utilization of medicines was calculated in DDD per 1000/inh/day. There was an increase of 41% in the number of patients treated with biological medicines. The reimbursement cost of biologicals increased by 21%; however, the per-patient reimbursement costs per diagnosis fell by 40% due to price decreases. Out of 21 reimbursed diagnoses, we saw a significant difference in prevalence (612 SD in 2016 to 1216 SD in 2020; p < 0.05). RA accounted for 2736 patients in 2016, increasing by 131% to 4662 patients in 2020; AS with 1933 patients in 2016 reached 3196 patients by 2020, and PsA with 1128 patients ranked third with a 75% increase. The cost of therapy of RA was the highest, accounting for appr. 15 mill Euro in 2016. The utilization decreased only for 2 INNs (infliximab and rituximab). All INNs experienced a nearly two-fold increase in their utilization: from 0.5244 to 0.9252 DDD/1000inh/day. The cost analysis shows an important place of biologicals for arthropathic diseases therapy; introduction of biosimilars leads to prices and cost decreases.

[1]  C. Bombardier,et al.  Health care costs of rheumatoid arthritis: A longitudinal population study , 2021, PloS one.

[2]  G. Petrova,et al.  Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria , 2021, Pharmaceuticals.

[3]  M. Samartín-Ucha,et al.  Direct costs in patients with chronic inflammatory arthropathies on biological therapy: a real-world data study. , 2020, Clinical and Experimental Rheumatology.

[4]  T. Shireman,et al.  Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis , 2020, Seminars in Arthritis and Rheumatism.

[5]  M. Kamusheva,et al.  Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis , 2018, Front. Pharmacol..

[6]  M. Kamusheva,et al.  Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines , 2018, Front. Pharmacol..

[7]  Li Wang,et al.  Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs , 2018, Rheumatology advances in practice.

[8]  J. Skoupá,et al.  Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries , 2017, Front. Pharmacol..

[9]  G. Deshpande,et al.  Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study , 2016, Drugs - Real World Outcomes.

[10]  T. Sokka,et al.  Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study. , 2016, Rheumatology.

[11]  R. Moots,et al.  Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs. , 2015, Clinical and experimental rheumatology.

[12]  V. Escudero-Vilaplana,et al.  The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use , 2015, Expert review of pharmacoeconomics & outcomes research.

[13]  Katherine E Henson,et al.  Risk of Suicide After Cancer Diagnosis in England , 2018, JAMA psychiatry.

[14]  E. Lubrano,et al.  Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies , 2014, BMC Musculoskeletal Disorders.

[15]  V. Schabert,et al.  Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care Population , 2013, Journal of managed care pharmacy : JMCP.

[16]  M. Bonafede,et al.  Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis , 2013, Journal of medical economics.